Based on human and preclinical studies , we hypothesized that a combination of low-dose anti-thymocyte globulin ( ATG ) and pegylated granulocyte CSF ( G-CSF ) would preserve cell function in patients with established T1D ( duration of T1D > 4 months and < 2 years ) .